Table 1. Clinical and laboratory... | American Society of Hematology

Table 1.

Clinical and laboratory features of patients with B-CLL

Patient	Age/Sex	Stage	Doubling time, mo	ZAP-70 status^*	Viable cells, % +10 μM nutlin†
1	65/M	0	44	Absent/low	53
2	71/M	0	25	Intermediate/high	46
3	75/M	I	36	Absent/low	47
4	63/M	I	49	Absent/low	60
5	63/M	0	96	Absent/low	52
6	69/M	II	12	Intermediate/high	53
7	57/M	0	32	Absent/low	72
8	74/F	I	12	Absent/low	72
9	60/M	0	24	ND	56
10	68/M	0	120	Absent/low	64
11	65/F	0	60	Intermediate/high	53
12	75/F	0	14	Absent/low	74
13	62/M	0	60	Absent/low	45
14	51/F	0	16	Intermediate/high	35
15	56/F	I	28	Intermediate/high	56
16	83/M	0	54	Absent/low	45
17	71/M	0	16	Intermediate/high	45
18	61/F	I	6	Intermediate/high	66
19	89/F	III	7	Absent/low	48
20	61/M	0	9	Absent/low	44
21	73/M	II	28	Absent/low	68
22	46/M	I	10	Intermediate/high	51
23	72/M	II	14	ND	38
24	68/F	II	2	Absent/low	68
25	75/M	IV	2	Intermediate/high	50
26	84/F	II	5	Absent/low	72
27	70/M	II	2	Absent/low	92
28	74/M	IV	130	Intermediate/high	55
29	59/F	IV	3	Absent/low	48

Patient	Age/Sex	Stage	Doubling time, mo	ZAP-70 status^*	Viable cells, % +10 μM nutlin†
1	65/M	0	44	Absent/low	53
2	71/M	0	25	Intermediate/high	46
3	75/M	I	36	Absent/low	47
4	63/M	I	49	Absent/low	60
5	63/M	0	96	Absent/low	52
6	69/M	II	12	Intermediate/high	53
7	57/M	0	32	Absent/low	72
8	74/F	I	12	Absent/low	72
9	60/M	0	24	ND	56
10	68/M	0	120	Absent/low	64
11	65/F	0	60	Intermediate/high	53
12	75/F	0	14	Absent/low	74
13	62/M	0	60	Absent/low	45
14	51/F	0	16	Intermediate/high	35
15	56/F	I	28	Intermediate/high	56
16	83/M	0	54	Absent/low	45
17	71/M	0	16	Intermediate/high	45
18	61/F	I	6	Intermediate/high	66
19	89/F	III	7	Absent/low	48
20	61/M	0	9	Absent/low	44
21	73/M	II	28	Absent/low	68
22	46/M	I	10	Intermediate/high	51
23	72/M	II	14	ND	38
24	68/F	II	2	Absent/low	68
25	75/M	IV	2	Intermediate/high	50
26	84/F	II	5	Absent/low	72
27	70/M	II	2	Absent/low	92
28	74/M	IV	130	Intermediate/high	55
29	59/F	IV	3	Absent/low	48

ND indicates not done.

ZAP-70 expression was evaluated by Western blot on CD19⁺ purified B-CLL cells.

Percentage of viability was measured by Trypan blue at 48 hours of treatment.